1. Home
  2. |Insights
  3. |Biosimilars India 2010

Biosimilars India 2010

Event | 09.30.10 - 10.01.10, 12:00 AM UTC - 12:00 AM UTC

With an estimated $25 billion of biologics coming off patent imminently, biosimilars present the pharma industry with most lucrative market opportunity for a long time. The pharma, biotechnology, CRO, and CMO organisations who prepare themselves today will reap the enormous biosimilars rewards tomorrow.

CPhI Conferences is delighted to present its 2nd Annual Biosimilars India 2010 conference. This two-day strategic event will provide all the key players within the biosimilars value chain with the opportunity to assess the market, determine the right technical strategy, and drive the development and registration of biosimilars products both here in India and overseas.

Teresa Rea will speak at this event.

Insights

Event | 02.20.25

Has the Buss Stopped? Recoupment Today

Has the Buss Stopped? Recoupment Today: In 1997, the California Supreme Court decided Buss v. Superior Court. In Buss, the court concluded that a liability insurer that defended a mixed action could seek reimbursement from the insured for the defense costs associated with the claims that were not even potentially covered. Since then, numerous courts have held that insurers are entitled to recoup their defense costs associated with uncovered claims or causes of action. On the other hand, a significant number of courts have rejected insurers’ right to recoupment, at least in the absence of a policy provision granting the insurer that right. Some commentators have even suggested that the current judicial trend might be away from permitting insurers to recoup their defense costs. Is that correct? Has the Buss stopped? This panel of coverage experts will analyze insurers’ claimed right to recoupment today, and offer their perspectives on what the law on recoupment should perhaps be and might be in the future.